SLCO2B1, solute carrier organic anion transporter family member 2B1, owns 12 transmembrane domains and is encoded by the SLCO2B1 gene in humans. It belongs to the organic anion-transporting polypeptide family of membrane proteins. This gene is conserved in chimpanzee, cow, rat, chicken, dog, mouse, Rhesus monkey, C.elegans, zebrafish, and frog. It has been reported that 192 organisms have orthologs with this gene. It’s broadly expressed in lung, liver, and 23 other tissues, and is involved in the uptake of sulfated steroids in placent and sodium-independent transport of organic anions.
|Basic Information of SLCO2B1|
|Protein Name||Solute carrier organic anion transporter family member 2B1|
|Aliases||KIAA0880, OATP2B1, OATPB, SLC21A9|
|Organism||Homo sapiens (Human)|
SLCO2B1 is also known as SLC21A9 which belongs to the 12-membrane-spanning superfamily of solute carriers. SLCO2B1 is an organic anion transporter and mediates uptake of sulfated steroids in placent and sodium-independent transport of organic anions, such as the prostaglandins PGD2, PGE1, PGE2, taurocholate, thromboxane B2, leukotriene C4, and iloprost. In addition, high expression of SLCO2B1 is reported to be involved in the resistance to androgen deprivation therapy in patients with prostate cancer. Also, SLCO2B1 expression level can be a potential prognostic biomarker for prostate cancer. The gene variants are associated with pathologic responses in prostate cancer, suggesting their potential role as biomarkers for abiraterone treatment. Moreover, SLCO2B1 variants are associated with prostate cancer progression and overall survival in patients treated with androgen deprivation. SLCO2B1 suppression can prevent gastrointestinal toxicity treated with anticancer drug SN-38. SLCO2B1 also plays a functional role in modulating the pathophysiological actions of prostaglandins.
Fig.1 Topology of SLCO2B1. (Bian, 2016)
This article demonstrates that the SLCO2B1 expression level can be a prognostic biomarker for prostate cancer.
This article indicates that SLCO gene variants are associated with pathologic responses in prostate cancer, and these variants can be potential biomarkers for abiraterone treatment.
This article shows the SLCO2B1 variants are associated with prostate cancer progression and overall survival in patients treated with androgen deprivation.
This article shows that SLCO2B1 suppression can prevent gastrointestinal toxicity treated with anticancer drug SN-38.
This article shows that simeprevir and asunaprevir can inhibit the function of SLCO2B1 and these inhibitions may result in clinically relevant drug-drug interactions when used with SLCO2B1 substrates.
With expertise and dedication, we have developed a series of advanced Magic™ membrane protein production platform to provide various high-quality membrane protein services to our clients. Aided by our versatile Magic™ anti-membrane protein antibody discovery platform, we also provide customized anti-SLCO2B1 antibody development services.
Creative Biolabs aims to provide high-quality products to numerous worldwide clients to facilitate their basic research, and we will be your best companion in membrane protein preparation field. Any customized consultant is welcomed. For more detailed information, please feel free to contact us.